Description
| Product Name: | SARS-Cov-2 Papain-Like Protease Recombinant Protein |
| Product Code: | RPES0008 |
| Size: | 10µg |
| Synonyms: | Papain-like Protease, PLpro, PL-PRO, pp1a, Replicase polyprotein 1a |
| Species: | SARS-CoV-2 |
| Expression Host: | E.coli |
| Mol Mass: | 35.8 kDa |
| AP Mol Mass: | 34 kDa |
| Tag: | None |
| Purity: | > 90 % as determined by reducing SDS-PAGE. |
| Endotoxin Level: | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Bio Activity: | Testing in progress |
| Sequence: | Glu1564-Lys1878 |
| Accession: | QHD43415.1 |
| Storage: | Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles. |
| Shipping: | This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C. |
| Formulation: | Supplied as a 0.2 μM filtered solution of 20mM Tris-HCl, 10 mM 2-Mercaptoethanol, 20% Glycerol, pH 7.5. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer in |
| Reconstitution: | Not Applicable |
| Background: | Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and deISGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons. |
